A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group.
18 Years
N/A
Both
Hepatic Complications, Malignant Neoplasm
Trial Information
A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group.
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose of bortezomib in patients with advanced malignancies
and varying degrees of liver dysfunction.
II. Determine the safety and tolerability of this drug in these patients. III. Determine the
pharmacokinetics and pharmacodynamics of this drug in these patients with mild, moderate, or
severe liver insufficiency.
IV. Examine the dietary influences on bortezomib disposition and efficacy. V. Examine the
influences of proteasome inhibition on CYP 450 activity.
OUTLINE: This is a multicenter, dose-escalation study. Patients are stratified according to
hepatic function (normal vs mild dysfunction vs moderate dysfunction vs severe dysfunction).
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients per stratum receive escalating doses of bortezomib until the maximum
tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2
of 6 patients experience dose-limiting toxicity.
[Note: Patients with normal hepatic function do not receive escalating doses of bortezomib.]
Inclusion Criteria:
- Histologically confirmed malignancy for which no known standard therapy that is
potentially curative or definitely capable of extending life expectancy exists
- Tumor types may include any of the following: solid tumors:
- Non-Hodgkin's lymphoma
- Hepatocellular carcinoma, as evidenced by liver mass, elevated alpha-fetoprotein
level (>= 500 ng/mL), and positive serology for hepatitis
- Pathological confirmation is not required
- Confirmatory evidence for a prior Hepatitis B infection (HBsAg, HBcAb and/or HBsAb)
required
- No symptomatic CNS metastases
- Brain metastasis allowed if the following criteria are met:
- Received prior definitive treatment (radiation and/or surgery
- Stable disease for >= 4 weeks
- Not currently on enzyme-inducing anticonvulsants and steroids
- Life expectancy of at least 12 weeks
- Absolute neutrophil count >= 1,000/mm^3
- Platelet count >= 100,000/mm^3
- Biliary obstruction for which a shunt has been placed allowed provided the shunt has
been in place for >= 10 days AND liver function is stable, defined as 2 measurements
taken >= 2 days apart that qualify the patient for the same hepatic dysfunction
stratum
- No biliary sepsis
- Creatinine =< 1.5 mg/dL
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No New York Heart Association class III or IV heart disease
- Not pregnant or nursing
- Negative pregnancy test
- No preexisting neuropathy >= grade 2
- No ongoing or active infection
- No other concurrent uncontrolled illness that would preclude study participation
- No psychiatric illness or social situation that would preclude study compliance
- More than 4 weeks since prior immunotherapy
- More than 4 weeks since prior biologic therapy
- No concurrent prophylactic colony-stimulating factors
- No concurrent immunotherapy
- No concurrent thalidomide
- Concurrent epoetin alfa or darbepoetin alfa for management of cancer-associated
anemia allowed
- Recovered from prior chemotherapy (not including liver function)
- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- No concurrent chemotherapy
- More than 2 weeks since prior radiotherapy
- No prior radiotherapy to > 50% of the bone marrow
- No concurrent radiotherapy
- More than 3 weeks since prior surgery
- No prior bortezomib
- No concurrent antiretroviral therapy for HIV-positive patients
- No other concurrent investigational agents
- Concurrent cytochrome P450 interacting agents are allowed provided they are used with
caution
- Concurrent bisphosphonate therapy allowed (e.g., pamidronate or zoledronate), except
during course 1 of bortezomib administration
- ECOG 0-2
- Fertile patients must use effective contraception during and for 30 days after study
participation
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
DLT
Outcome Time Frame:
21 days
Safety Issue:
Yes
Principal Investigator
Patricia LoRusso
Investigator Role:
Principal Investigator
Investigator Affiliation:
Wayne State University
Authority:
United States: Food and Drug Administration
Study ID:
NCI-2009-00059
NCT ID:
NCT00091117
Start Date:
July 2004
Completion Date:
Related Keywords:
- Hepatic Complications
- Malignant Neoplasm
- Neoplasms
- Liver Diseases
Name | Location |
|---|---|
| Johns Hopkins University | Baltimore, Maryland 21205 |
| City of Hope Medical Center | Duarte, California 91010 |
| Wayne State University | Detroit, Michigan 48202 |
